Furthermore, 2-bromopalmitate activates anti-tumor immunity in colon cancer mice by inhibiting the palmitoylation of PD-L1 or silencing DHHC3, an enzyme required for the palmitoylation of PD-L1, which provides new ideas for overcoming PD-L1-mediated immune evasion [186]. This evidence concerns the gene CD274 and colonic neoplasm.